Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Kyle Boucher
Period: Reporting periods mapped to calendar 2025 Q2 – 2026 Q1 (4 quarters; questions recorded in 3).
- Questions
- 6on tracked calls
- Challenge rate
- 0%none of 6 questionsLimited sample
- Companies
- 1questioned at least once
- Reporting periods
- 3with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 6 of 6 questions from 1 company
TECHBio-Techne6 questions · 3 reporting periods · 0 of 6 challenging
Calendar 2026 Q1
I guess beyond biotech performance, I mean, is there anything else that's sort of getting worse?
Show response
Kim provided comprehensive end market flyby: pharma strong, academic stabilizing, China positive four quarters running. Cell therapy ex-2 customers at 50% growth, spatial at mid-double digits with COMET at 65%. Only biotech remains the detractor.
how sustainable do you think these levels of growth are going forward? I mean, do they face easy comps year-over-year?
Show response
Kim noted customer count up 3% with pipeline progression from Phase I to II (15 to 18 programs). Cell therapy trials globally increasing with mix shift from gene to cell therapy. 20% TTM growth is the minimum bar. Wilson Wolf grants show 50% attachment rate with Bio-Techne cytokines.
Calendar 2025 Q3
Was there any catch-up in fiscal Q1 from some of those disruptions you saw at the end of the last fiscal year?
Show response
Kim confirmed no catch-up effect, spatial improvement reflects broad activity-level recovery in RNAscope reagents and growing instrument order book rather than one-time timing.
next quarter, assuming the same level of growth, minus 1%, what does that sort of imply for the EBIT margin
Show response
Jim declined specific Q2 margin guidance but noted additional productivity actions taken in Q1 to prepare for Q2 cell therapy headwinds. Expressed confidence in full-year 100bp expansion target with potential upside.
Calendar 2025 Q2
how does pharma sort of fit within that framework?
Show response
Jim explained the low-single-digit guide assumes more of the same Q4 dynamics: double-digit large pharma offset by weak biotech and academic. Acknowledged MFN risk could soften pharma but sees academic potentially being overly conservative as an offset.
Could you quantify how much maybe pull forward you saw in the fiscal fourth quarter?
Show response
Kim attributed China strength to both stimulus funding release and pre-tariff pull-forward purchasing behavior. Cautioned against extrapolating double-digit results, expecting stable modest growth trajectory excluding one-time factors.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| TECH Bio-Techne | 6 | 0%none of 6 questions |
- TECHBio-Techne · 6 questions0%none of 6 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q2 | 2 | 0%none of 2 questions | 1 |
| 2025 Q3 | 2 | 0%none of 2 questions | 1 |
| 2025 Q4 | No questions recorded | — | — |
| 2026 Q1 | 2 | 0%none of 2 questions | 1 |
- 2025 Q22 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q32 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q4No questions recorded
- 2026 Q12 questions · challenge rate 0% (none of 2 questions) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Revenue Growth3
- Guidance Reliability3
- Demand2
- Product Launch1
- Margin1
- Macroeconomic1
- Trade Tariffs1